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Cystine–glutamate antiporter 
deletion accelerates motor 
recovery and improves histological 
outcomes following spinal cord 
injury in mice
Lindsay Sprimont1, Pauline Janssen2, Kathleen De Swert1, Mathias Van Bulck3, Ilse Rooman3, 
Jacques Gilloteaux1,4, Ann Massie2 & Charles Nicaise1*
xCT is the specific subunit of System xc-, an antiporter importing cystine while releasing glutamate. 
Although xCT expression has been found in the spinal cord, its expression and role after spinal cord 
injury (SCI) remain unknown. The aim of this study was to characterize the role of xCT on functional 
and histological outcomes following SCI induced in wild-type (xCT+/+) and in xCT-deficient mice 
(xCT−/−). In the normal mouse spinal cord, slc7a11/xCT mRNA was detected in meningeal fibroblasts, 
vascular mural cells, astrocytes, motor neurons and to a lesser extent in microglia. slc7a11/xCT 
gene and protein were upregulated within two weeks post-SCI. xCT−/− mice recovered muscular 
grip strength as well as pre-SCI weight faster than xCT+/+ mice. Histology of xCT−/− spinal cords 
revealed significantly more spared motor neurons and a higher number of quiescent microglia. In 
xCT−/− mice, inflammatory polarization shifted towards higher mRNA expression of ym1 and igf1 
(anti-inflammatory) while lower levels of nox2 and tnf-a (pro-inflammatory). Although astrocyte 
polarization did not differ, we quantified an increased expression of lcn2 mRNA. Our results show that 
slc7a11/xCT is overexpressed early following SCI and is detrimental to motor neuron survival. xCT 
deletion modulates intraspinal glial activation by shifting towards an anti-inflammatory profile.
Abbreviations
xCT  Specific subunit of the cystine–glutamate exchanger
slc7a11  Solute carrier family 7 member 11
SCI  Spinal cord injury
ALS  Amyotrophic lateral sclerosis
MS  Multiple sclerosis
EAE  Experimental autoimmune encephalitis
GSH  Glutathione
EAAT  Excitatory amino acid transporter
ish  In situ hybridization
Minutes to days following spinal cord injury (SCI), hemorrhage, ion dysregulation, production of reactive oxy-
gen species and excitotoxicity are amongst the pathological events responsible for the propagation of damage to 
spared spinal tissue surrounding the epicenter. During this so-called secondary injury, the volume of the initial 
trauma expands and leads to additional tissue loss, and therefore worsens the functional  deficits1. Within minutes 
post-SCI, abnormal-to-toxic levels of glutamate are reached in the extracellular space and this can persist for 
more than a  week2–5. Beside a focal glutamate rise, glutamate homeostasis is also disturbed at remote lesioned 
sites, likely via spreading mechanisms involving activated glial  cells6. Oligodendrocytes and motor neurons are 
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amongst the most vulnerable cells to glutamate excitotoxicity as they have a high expression of amino-3-hydroxy-
5-methylisoazol-4-propionate receptor and N-methyl-D-aspartate receptor respectively, and they are endowed 
with limited calcium buffering  abilities3,7.
In the spinal cord, glutamate is the most represented neurotransmitter whose release is timely regulated, 
which supports an efficient and transient neurotransmission, while avoiding excessive extracellular glutamate 
concentrations. In physiological conditions, glutamate is maintained at very low levels in the synaptic cleft and 
in the extrasynaptic spaces, through a variety of membranous transporters on neuronal or non-neuronal cells. 
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High affinity excitatory amino-acids transporters (EAATs) are expressed by astrocytes and account for up to 
90% of synaptic glutamate re-uptake8. Emerging as another player in glutamate homeostasis, System xc- has 
been identified as the major source of glutamate released in the extrasynaptic spaces of the hippocampus and 
the  striatum9–12. System xc− is a Na+ -independent electroneutral antiporter composed of xCT specific subunit 
acting as the cysteine–glutamate antiport and bound to the 4F2 heavy chain subunit involved in its membrane 
 trafficking13,14. xCT protein is encoded by the slc7a11 gene located on chromosome 3 in mice and on chromo-
some 4 in humans. xCT functions to export one molecule of glutamate in exchange for one cystine imported, in 
a 1:1 ratio. Cystine is further reduced intracellularly into cysteine that serves as a building block for glutathione 
(GSH)15,16. The cellular expression of xCT is still a matter of debate; some authors found it in  microglia17–19, while 
others in astrocytes or  oligodendrocytes20–23, but insofar not in  neurons19,22. The activity of xCT is induced in 
presence of reactive oxygen species or inflammatory  stimuli24–26. This suggests that an enhanced activity, while 
beneficially boosting GSH production, can at the same time lead to inopportune glutamate release. Several lines 
of evidence argue towards an active contribution of xCT in the progression of spinal cord disorders. For instance, 
xCT protein expression is highly upregulated in the spinal tissue of patients suffering from multiple sclerosis 
(MS) or amyotrophic lateral sclerosis (ALS)27,28. Moreover, xCT deficiency produces significant improvements of 
disease outcomes in  MS28,29 and  ALS27 animal models, suggesting that inhibition of glutamate release via System 
xc− , or another mechanism, would somehow confer neuroprotection.
xCT being a cystine–glutamate antiporter, we hypothesized that it could contribute to glutamate excitotoxic-
ity, alleviate oxidative stress, or even modulate inflammation following spinal cord injury (SCI). To elucidate the 
role of System xc-, wild-type (xCT+/+) and xCT knock-out (xCT−/−) mice were subjected to cervical contusive 
SCI. In both injured groups of animals, we assessed functional motor outcomes, histological findings, completed 
by molecular markers of glial activation and inflammation polarization. In addition, we provide new data on 
cellular distribution of slc7a11/xCT mRNA in the normal and injured mouse spinal cord.
Results
slc7a11/xCT is mostly expressed in meningeal cells and spinal astrocytes, and is upregulated 
following SCI. The expression of slc7a11/xCT mRNA was investigated using in situ hybridization (ish) at 
several cervical levels of the adult C57BL/6J mouse spinal cord. The results consistently showed chromogenic 
deposits in the normal spinal cord with a preferential distribution throughout the gray matter and the pia mater 
(Fig. 1a, Supplementary Fig. 1a). Spinal tissue from xCT−/− mouse was used as negative control; absence of 
slc7a11 signal demonstrated the specificity of the probe (Supplementary Fig. 1b). Mouse genotype (+/+ , + /− 
or −/−) was confirmed by PCR and real-time quantitative PCR (Supplementary Fig. 1c). In the gray matter of 
xCT+/+ mice, slc7a11 mRNA labeling was detected in the neuropil; in the ventral horns as wells as in the inter-
mediate and dorsal layers, mostly scattered between neuronal cell bodies (Fig. 1a, insets 1 and 3). Rexed laminae 
I, II and III were particularly enriched in cells bearing slc7a11 mRNA (Fig. 1a, inset 3). Cells that belonged to 
the meningeal layers also showed strong slc7a11 probe labeling as well as mural cells along the perforating blood 
vessels (Fig. 1a, inset 2). Following unilateral spinal cord injury, the signal density for slc7a11 probe drastically 
increased compared to the contralateral side or compared to an uninjured spinal cord (Fig. 1b). The overall 
amount of slc7a11 mRNA in the lesion was 2.7 times higher within the fourth day post-injury (Kruskal–Wal-
lis ANOVA; uninjured vs. 4 days post-SCI; p = 0.0413), with a tendency towards a plateau at 2- and 6-weeks 
post-SCI (Fig. 1c). Using anti-xCT antibody, we showed an upregulation of spinal xCT protein expression at 
the second week post-SCI (Kruskal–Wallis ANOVA; uninjured vs. 2 weeks post-SCI; p = 0.0058) (Fig. 1d, e). 
Protein extracts from xCT−/− spinal cords were used as negative control to verify the specificity of the antibody. 
Although many studies rely on a predicted molecular weight at 55.5 kDa, a band between 34 and 43 kDa was 
reliably detected in all CNS samples from xCT+/+ mice, that was absent from xCT−/− matched tissue (Supple-
mentary Fig. 1d). Extra bands at higher molecular weight (around 130 kDa) were also revealed; further inves-
Figure 1.  Cellular slc7a11/xCT gene expression in the mouse spinal cord. A probe targeting slc7a11 mRNA 
was applied onto uninjured and injured spinal cords. The chromogenic signal of the in situ hybridization was 
revealed as pink deposits, whose size was proportional to the local amount of transcripts (a,b). In the normal 
spinal cord, slc7a11/xCT mRNA expression was predominantly detected in nervous cells satellite to motor 
neurons (a, inset 1), in the meningeal layer and along the wall of the perforating blood vessels (a, inset 2), and 
in the neuropil around the dorsal horn neurons (a, inset 3). A higher abundance of transcripts was detected in 
the lesion area from spinally-injured mice (b). qRT-PCR confirmed the overall increased expression of slc7a11/
xCT mRNA in injured spinal cords, significantly peaking at 4 days post-injury (c) (*p < 0.05, Kruskal–Wallis 
ANOVA test, Un. n = 3; 4d n = 8; 2w n = 3; 6w n = 3). Immunoblot showing xCT and GAPDH protein expression 
at different timings post-SCI (d). Full length blot of xCT detection is displayed where xCT specific band was 
detected at approximately 40 kDa. GAPDH was used as loading control. Uncropped images are available in 
Supplementary Fig. 2. Compared to uninjured tissue (Un.), xCT was upregulated at the protein level at two 
weeks post-injury (e) (*p < 0.01, Kruskal–Wallis ANOVA test, Un. n = 4; 1w n = 4; 2w n = 5). Fluorescent slc7a11 
in situ hybridization (orange) and immunofluorescent co-labeling (green) of GFAP, Iba1, p25a, MAP2 and 
vimentin in uninjured spinal cords (f). The majority of slc7a11 + cells were co-labeled with GFAP, vimentin, 
MAP2 and Iba1 (white arrows) (g). The nuclei were counterstained with DAPI (blue). slc7a11 expression was 
rarely detected in p25a + oligodendrocytes. Injury did not significantly modify the cellular expression profile 
of slc7a11 (p = n.s., Mann–Whitney test, n = 3 spinal slices in each group). Data are expressed as mean +/− 
SEM. Scale bars = 250 µm in a and 10 µm in f. Abbreviations : n.d. = not done, as MAP2 + motor neurons were 
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tigations did not allow to conclude on the nature of the bands. Next, the cellular expression of slc7a11 mRNA 
was investigated on spinal slices using double labeling for astroglial (GFAP), microglial (Iba1), oligodendroglial 
(p25alpha), neuronal cells (MAP2) and intermediate filaments (vimentin). Slc7a11 + cells were co-labeled with 
GFAP, MAP2 and Iba1 at various degrees, but very rarely with p25alpha (Fig. 1f). Quantification of double-
labeled cells in a healthy spinal cord showed that the vast majority of slc7a11 + cells were immunoreactive for 
GFAP (61%), vimentin (43%), MAP2 (64%) and to a lesser extent for Iba1 (4%) (Fig. 1g). Unlike GFAP being 
almost exclusively expressed by astrocytes, vimentin was also found in meningeal fibroblasts. Both cell types 
showed significant slc7a11 probe co-labeling (Fig. 1f). One week after SCI, the proportion of slc7a11 + cells co-
labeled with GFAP, vimentin, p25alpha or Iba1 did not significantly change (Fig. 1g).
Spinally-injured xCT−/− mice had a faster body weight and motor recovery than wild-type lit-
termates. To elucidate the role of System xc− following SCI, wild-type (xCT+/+) and knock-out (xCT−/−) 
mice were subjected to unilateral cervical contusive injury. To follow the evolution of forelimb motor function, 
both groups of injured mice were monitored for 6 weeks post-SCI using weight, paw preference test, and grip 
strength testing. Within the first week after SCI, the weight of mice dropped about 2 g, and progressively returns 
to pre-SCI basal level the following weeks (Fig. 2a). Injured xCT−/− mice regained weight faster at 3- and 4- 
weeks post-SCI than xCT+ /+ mice (two-way ANOVA; F(1,142) = 36.14 for genotype comparison xCT+/+ vs. 
xCT−/−; p = 0.0141 and p = 0.0264 at 3- and 4- weeks post-SCI respectively). During exploration in the cylinder 
paw preference test, there was an impairment in the animals’ ability to use the ipsilateral forepaw after SCI. How-
ever, no difference in forepaw use between both genotypes could be found during the entire follow-up period of 
6 weeks (Fig. 2b). Compared to pre-SCI condition, both groups undergoing contusion SCI showed an evident 
drop in their ipsilateral forelimb grip strength the first week post-injury (Fig. 2c). The injured xCT−/− mice sub-
sequently recovered a stronger grip force in the affected forelimb than xCT+/+ littermates (two-way ANOVA; 
F(1,134) = 20.97 for genotype comparison xCT+/+ vs. xCT−/−; p = 0.0004 and p = 0.0401 at 2- and 3- weeks post-
Figure 2.  Evolution of weight and motor function in injured xCT+/+ and xCT−/− at different timing post-
injury. xCT−/− mice recovered pre-SCI weight and gained weight faster than xCT+/+ between 3 and 4 weeks 
post-injury (a). Use of forelimbs, either ipsilateral or contralateral (or both) to the spinal lesion, was not different 
between injured xCT+/+ and xCT−/− mice (b). Grip strength test showed a better recovery of the ipsilateral 
grip strength for xCT−/− mice than for xCT+/+ mice at 2- and 3- weeks post-injury (c). Both groups of mice 
recovered similarly at later time points. The contralateral grip strength was not impaired by the unilateral spinal 
cord injury (d). *p < 0.05 and ***p < 0.001, two-way ANOVA followed by Sidak’s multiple comparisons, n = 10–12 
mice/group between -1 and 2 weeks post-injury, n = 4–8 mice/group between 3 and 6 weeks post-injury. Data 
are expressed as mean +/− SEM.
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SCI respectively). Contralateral forelimb score was not affected at any time point, consistent with a unilateral 
nature of the lesion (Fig. 2d).
Spinal GSH levels and oxidized proteins are similar in injured xCT+/+ and xCT−/−. As System 
xc− acts as an importer of cystine across the membrane and is as such involved in the replenishment of intracel-
lular glutathione, we sought to know to what extent the deletion of the xCT subunit would alter GSH production. 
In absence of injury, there was not significant difference in the amount of GSH in xCT−/− spinal cords compared 
to xCT+/+ tissues (two-way ANOVA; F(1,19) = 1.459 for genotype comparison xCT+/+ vs. xCT−/−; p = 0.1077) 
(Fig. 3a). This suggests that xCT−/− mice are still able to build GSH and, in a way, compensate for the loss of 
cystine import, through alternative pathways. As measured at two weeks, SCI induced a significant depletion of 
spinal GSH levels in injured xCT+/+ mice (two-way ANOVA; F(1,19) = 14.74 uninjured vs. injured; p = 0.0011), 
that yielded the same magnitude in the xCT−/− group. GSH content was therefore similar in both injured groups 
following SCI and GSH levels per se cannot account for the better early recovery observed in xCT−/− mice. 
Formation of carbonylated proteins has been described following SCI, consequently to oxidative stress during 
the secondary phase of SCI. Quantitative assessments of total carbonylated proteins, as referred as “oxidation 
index”, showed variability within a same experimental group and did not reveal any difference between injured 
xCT+/+ and xCT−/− tissues (Fig. 3b, c).
The number of spared motor neurons is greater in injured xCT−/− spinal cords. In order to 
understand why xCT-deficient mice recovered earlier following SCI, we sought to correlate functional findings 
with histological outcomes. Occurring in hours-to-days after the initial traumatic contusion, the SCI lesion 
extends away from the epicenter (Fig. 4a) in a rostro-caudal fashion. The lesion is characterized by a disruption 
of spinal cord architecture, with a loss of neuronal cell bodies, demyelination or damages of nerve fibers, infiltra-
tion by immune cells and activation of glial cells. Lesion area was first analyzed at different distances along the 
cervical spinal cord in injured xCT+/+ and xCT−/− mice (Fig. 4b). Neither 2 weeks nor 6 weeks post-SCI did 
the lesion surface (Fig. 4c) or lesion volume (Fig. 4d) differ between both genotypes. In order to count the motor 
neuron cell bodies ipsilateral to the lesion, each spinal slice has been divided into 4 quadrants with the center of 
the central canal as the origin of the reference system. Counts were restricted to those cells that met the criteria of 
motor neurons, as stated in the Methods (Fig. 4e, inset). Compared with the xCT+/+ mice, injured xCT−/− mice 
Figure 3.  Glutathione levels and oxidative stress-related markers following SCI. Spinal GSH content in pre-
injury and injury groups. Injured xCT+/+ and xCT−/− mice had equal amount of GSH two weeks after SCI 
(a). GSH levels are significantly decreased after injury in xCT+/+ mice. **p < .01, two-way ANOVA followed 
by Sidak multiple comparisons test, n = 5–7 mice/group. Protein oxidation detection kit was used to quantify 
the amount of carbonylated proteins in the spinal cord at 2 weeks post-injury in injured xCT+/+ and xCT−/− 
mice (b). When normalized to actin, the oxidation index (a.u.) did not show any significant difference between 
groups (c). Mann–Whitney test, n = 5 mice/group. Data are expressed as mean +/− SEM.
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Figure 4.  Quantification of lesion size, motor neuron and oligodendrocyte number in injured xCT+/+ and xCT−/− 
spinal cords. The diagram depicts how the unilateral lesion extends rostro-caudally from  − 1000 to + 1000 µm 
around the epicenter (a). The epicenter (set at 0 µm) was defined as the spinal level where the area of lesioned tissue 
is maximal. Representative micrographs of the lesion epicenter is shown for xCT+/+ (left) and xCT−/− (right) mice 
(b). Quantification of lesioned area (in percentage of ipsilateral hemicord) or lesion rostro-caudal extension did not 
show any difference between groups at 2 or 6 weeks post-injury (c). Quantification of lesion volume did not show 
any difference between groups at 2 or 6 weeks post-injury (d). As depicted, the number of spared motor neurons was 
counted in the inferior quadrants of both contralateral and ipsilateral sides, including the ventral horn and part of 
the intermediate column (e). For some distances along the lesion, ipsilateral motor neuron number was significantly 
higher in injured xCT−/− mice than in the xCT+/+ mice, at both 2 and 6 weeks post-injury (f). Data are expressed 
as mean +/− SEM. *p < 0.05, Mann–Whitney test, n = 3–4 mice/group. Using anti-p25a immunohistochemistry, the 
number of spared oligodendrocytes was evaluated in the injured xCT+/+ and xCT−/− hemicords, at three distances 
from the epicenter, 0 µm, + 500 µm and + 1000 µm (g,h). two-way ANOVA followed by Sidak multiple comparisons 
test, n = 3–4 mice/group. Data are expressed as mean +/− SEM. Scale bars = 50 µm in panel g.
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showed an increased number of ipsilateral spared motor neurons at multiple distances from the lesion epicenter 
at both 2 and 6 weeks (Mann–Whitney test; p < 0.05 at multiple distances) (Fig. 4f). The number of motor neu-
rons contralateral to the lesion did not differ between genotypes.
For further analysis of glial cell number, the lesion epicenter (0 µm) and two regions caudal to it (respectively 
at +500 and +1000 µm distances) were considered. Like motor neurons, oligodendrocytes are likely to undergo 
cell death at the lesion epicenter and their loss can be correlated to functional motor impairment. Therefore, the 
number of oligodendrocytes was investigated using anti-p25a immunohistochemistry (Fig. 4g). As expected, 
a drastic loss of p25a immunoreactivity was observed in the grey and white matter at 2 weeks post-SCI in both 
groups (inset in Fig. 4g). The quantification of p25a + cells did not reveal any difference in the number of oligo-
dendrocytes (Fig. 4h), even at later time points when oligodendrocytes—or their precursors—are supposed to 
have started the remyelination process.
Reactive astrogliosis is not significantly impacted in injured xCT−/− mice. As we previously found 
an expression of xCT in spinal astrocytes, we wondered how its deficiency would impact on their reactivity fol-
lowing SCI. Anti-GFAP immunohistochemistry was applied onto the injured spinal slides to evaluate the extent 
of reactive astrogliosis in both groups (Fig. 5a). The number of GFAP + astrocytes in the ipsilateral hemicord 
was counted at different distances around the epicenter and did not reach the statistical difference (Fig. 5b). We 
sought to use a more sensitive marker of reactive astrocytosis by quantifying the transcript of lipocalin-2 (lcn2) 
at two weeks post-SCI. lcn2 mRNA was significantly upregulated in xCT−/− spinal cords compared to wild-type 
littermates (Mann–Whitney test; p = 0.0001) (Fig. 5c). We next used a set of molecular markers to character-
ize the polarization of reactive astrocytes towards classic proinflammatory versus neuroprotective phenotypes. 
Accordingly, we compared mRNA expression levels of specific astrocyte-associated proinflammatory (c3, gbp2, 
ligp1, clcf1) and neuroprotective (serping1, emp1, ptgs2)  genes30. None of the mRNAs investigated showed a dif-
ferential expression between injured xCT+/+ and xCT−/− spinal tissues at 2 weeks post-injury (Fig. 5d).
Injured xCT−/− spinal cords accumulate more ramified microglia/macrophages, bearing an 
anti-inflammatory phenotype. We first characterized the number of spinal microglia/macrophages using 
anti-Iba1 immunohistochemistry (Fig. 5e). According to morphology-based  criteria31, thin and highly ramified 
Iba1 + cells were considered as inactivated/resting “type A” microglia/macrophages and hypertrophied amoeboid 
Iba1 + cells devoid of cell process were considered as fully activated “type D” microglia/macrophages; type B and 
type C being intermediary activated states. Significant changes in cell number or shape were observed at two 
weeks post-SCI in the injured xCT−/− spinal cords, with an increased number of A microglia/macrophages in 
the lesion epicenter and in regions caudal to the epicenter (Mann–Whitney test, p = 0.028, p = 0.028 and p = 0.028 
at epicenter, 500 µm and 1000 µm respectively), together with a decreased number of type B microglia 500 µm 
away of the epicenter (Mann–Whitney test, p = 0.029) (Fig. 5f). At 6 weeks post-SCI, there was also a trend for 
a higher number of type A microglia/macrophages in the xCT−/− spinal cords (Mann–Whitney test, p = 0.059). 
As the deletion of xCT had been shown to influence M1/M2 microglia polarization in the spinal cord of a mouse 
model with symptomatic  ALS27, we sought to know how xCT+/+ or xCT−/− microglia/macrophages behave fol-
lowing SCI. Using a battery of molecular markers, we pointed out an imbalance in the inflammatory polarization 
at 2 weeks post-injury. Among the pro-infammatory genes, nox2 and tnf-a were downregulated (Mann–Whit-
ney test, p = 0.050 and p = 0.027 respectively) while among the anti-inflammatory genes, ym1 and igf-1 were 
upregulated (Mann–Whitney test, p = 0.042 and p = 0.031 respectively) in the injured xCT−/− mice (Fig. 5g).
Discussion
In the present manuscript, we sought to characterize the cellular distribution of xCT expression in the normal 
and injured mouse spinal cord, as well as the effect of xCT deficiency on functional and histopathological SCI 
outcomes. Based on a validation approach using specific ish probe and xCT knock-out tissue, we first showed that 
slc7a11/xCT mRNA was significantly detected in the normal mouse spinal cord and was preferentially distributed 
in meningeal cells, vascular mural cells, astrocytes, microglia and motor neurons. As demonstrated by the double 
labeling, slc7a11/xCT mRNA was not found in the satellite oligodendrocytes. Our results, although based on 
in situ gene expression, are partly in line with those showing xCT protein in meningeal  cells32,33, in astrocyte 
 subpopulations23,34,35 and in  microglia17–19,27,32,35–37, while questioning an expression by  oligodendrocytes20–22,34 
or neuron subtypes described  elsewhere19,22,37. Instead, slc7a11/xCT ish signal was widely distributed in gray 
matter neuropil where numerous neuronal and glial processes interwove, with a high density throughout Rexed 
laminae I to III. The reason for such an enrichment is unknown but one can hypothesize that a glial glutamate 
transporter, in close proximity to sensory neurons, could locally modulate the glutamatergic neurotransmission 
and the sensory processing. Recent data on xCT protein localization in the adult mouse spinal cord support our 
ish  findings38. After injury, the cell types expressing xCT mRNA were unchanged, taking into consideration the 
limited set of molecular markers herein investigated.
Following SCI, slc7a11/xCT gene expression was upregulated, as early as the fourth day post-injury. This 
high expression was not statistically significant at later timepoints but, still plateaued for a duration lasting up to 
6 weeks post-injury. Using a commercial anti-xCT antibody, whose specificity was validated on knock-out CNS 
homogenates (brain and spinal cord), we confirmed that xCT protein level significantly increased during the sub-
acute phase of experimental SCI. The sub-acute phase—from first hours to two weeks post-SCI—is characterized 
by an overall dysregulation of ions and neurotransmitters, blood–brain barrier leakages, vascular remodeling, 
local energy shortage, production of inflammatory mediators and free radicals from recruited immune cells or 
resident activated glial cells. Altogether, these changes disrupt the spinal homeostasis one way or another, and 
contribute to the secondary neuronal damage. Given the dual role of xCT in CNS tissue homeostasis and its 
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early overexpression following SCI, we wondered how the lesion extension, nerve cell survival, glial activation 
or neuro-inflammation would be impacted in xCT knock-out mice. On one hand, the consequence of System 
xc− deficiency could be deleterious by reducing the import of cystine and affecting the anti-oxidant capacity; 
on the other hand, it could decrease the threshold for excitotoxicity and thus protect surrounding spinal tissue.
In this study, we showed that spinally-injured xCT knock-out mice had a faster weight and grip strength 
recovery than wild-type littermates, especially during the first two weeks post-injury, which suggests an early 
involvement of xCT on functional recovery. Albeit the rostro-caudal extension and volume lesion were similar 
in both genotypes after injury, the analysis of spinal tissues demonstrated that motor neuron loss and activated 
microglia, as well as the levels of pro-inflammatory markers, were less pronounced in injured xCT−/− mice. 
As xCT mRNA is expressed by both non-neuronal cells and motor neurons, the impact of its absence on neu-
ron survival can be explained by either a cell autonomous or a non-cell autonomous protective effect. Sup-
porting the influence of non-neuronal System xc−, an in vitro study demonstrated that neuronal killing by 
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macrophage-mediated glutamate release was dependent on System xc−  activity39. Another in vitro model using 
neuron-astrocyte co-culture showed that, during hypoglycemic stress, glutamate released from astrocytes via Sys-
tem xc− is largely responsible for excitotoxic neuron  death40,41. Specifically, in the spinal cord, it has been shown 
that the local activation of System xc−, upon intraspinal LPS plus cystine administration, exerts neurotoxicity 
towards (motor)  neurons36. Glutamate excitotoxicity is classically described as one of the precipitating events 
leading to secondary motor neuron death after  SCI1–3,42. Abnormal extracellular glutamate levels are common at 
the lesion epicenter due to uncontrolled release during neuronal death but also due to the chronic downregula-
tion of astrocytic  EAATs1–3,42. Increased expression or activity of System xc− by activated glial cells at the SCI 
epicenter could add to the unwanted extracellular glutamate accumulation. Measuring System xc− activity in 
the spinal cord is technically challenging and would have implied for instance in vivo microdialysis or specific 
radiolabeled  ligands43. Although very informative, we did not implement these approaches in the present SCI 
paradigm. Instead, we quantified the intraspinal levels of glutathione pre- and post-SCI. The intraspinal levels 
of the reduced form of glutathione were equally lowered in both genotypes after injury, likewise the levels of 
carbonylated proteins, common markers of oxidative  stress44. Overall, this suggests that xCT deficiency in injured 
knock-out mice does not deleteriously alter the levels of anti-oxidant countermeasures.
Surprisingly, the loss of oligodendrocytes was similar in both spinally-injured genotypes whereas we could 
have expected a difference in cell survival if glutamate excitotoxicity was suspected as the mechanism of System 
xc- neurotoxicity. Indeed, just like motor neurons, oligodendrocytes express significant levels of calcium-perme-
able ionotropic glutamate receptors, making them susceptible to excitotoxic cell death. The main limitation in 
the interpretation of this result is that the p25a marker labels mature oligodendrocytes as well as oligodendrocyte 
precursor cells, known to highly proliferate as early as 1-week post-injury45. Therefore, we may have not caught 
the detailed picture of oligodendrocyte loss looking at two weeks post-injury. In the future, this should be taken 
into consideration as several reports also point out a non-cell autonomous effect of System xc- on oligodendrocyte 
survival in models of demyelinating  diseases18,28.
In a number of experimental models of CNS disorders, xCT inhibition, using either genetic or pharmaco-
logical approaches, has been found to be more often neuroprotective than deleterious e.g. in 6OHDA-induced 
Parkinson’s  disease12 and middle cerebral artery  occlusion15. With respect to spinal cord diseases, xCT deletion in 
 SOD1G37R mice slows down ALS disease course by mitigating spinal motor neuron loss and microglia  activation27. 
In mouse models of experimental autoimmune encephalomyelitis, mutant  Slc7a11sut/sut mice and mice treated 
with xCT inhibitors sulfasalazine or S-4-carboxyphenylglycine showed both better clinical outcomes, associated 
with enhanced oligodendrocyte survival and reduced immune cell  infiltration28. These data strengthen the idea 
that xCT upregulation or enhanced activity during neurologic conditions compromises spinal tissue integrity and 
neuron/oligodendrocyte survival. The mechanism underlying the neuroprotection in the cases of ALS or EAE 
experimental models combined with xCT deficiency, clearly involved an anti-inflammatory polarization of the 
immune response. In an attempt to extend Evonuk’s findings, Merckx and colleagues induced EAE in xCT full 
knock-out mice but did not observe any difference in the clinical outcomes between wild-type and xCT-deficient 
 mice29. However, in chimeric animals expressing xCT in their entire body except for their bone marrow-derived 
cells -and thus immune cells- the authors found better clinical scores compared to wild-type mice after EAE 
induction. This suggests that System xc− modulates macrophage/microglia function, most likely via changes in 
glutamate release or intracellular redox  balance27,36.
Several lines of evidence now support that System xc− regulates the way microglia and macrophages polarize 
or activate along their inflammatory  response27,35. In our model of SCI, we showed an impact of xCT deletion 
on the degree of microglia/macrophage activation; within the first two weeks post-SCI, injured xCT−/− spinal 
cords had an increased number of resting “type A” microglia/macrophage at several distances around the epi-
center. It would have been interesting to decipher from microglia or macrophages which cells were involved in 
such difference, by using for instance specific TMEM119 microglia marker. Overall, it means that the activation 
Figure 5.  Assessment of astrocyte and microglia activation in injured xCT+/+ and xCT−/− spinal cords. Spinal 
cords from both genotypes were immunostained with GFAP antibody. Representative GFAP immunolabeling at 
the epicenter at 2 weeks post-injury for both genotypes (a). The counting of GFAP-positive cells was performed 
in the ipsilateral hemicord at epicenter, and + 500 µm and + 1000 µm caudal to the epicenter (b). No significant 
change in astrocyte number was observed. two-way ANOVA followed by Sidak multiple comparisons test, n = 4 
mice/group. Data are expressed as mean +/− SEM. A set of molecular markers was applied to assess astrocyte 
activation and polarization towards pro-inflammatory or anti-inflammatory phenotype at 2 weeks post-injury. 
While lcn2 was significantly upregulated in xCT−/− spinal cord, no other changes in astrocyte markers were 
observed between genotypes (c,d). ***p < 0.001, Mann–Whitney test, n = 3–4 mice/group. Data are expressed as 
mean + /− SEM. Spinal cords from both genotypes were immunostained with Iba1 antibody and morphology-
based-microglia activation was sorted according to four types: from a morphology with long and thin ramified 
processes type A to an amoeboid morphotype D (e). The sorting of Iba1-positive cells was performed in the 
ipsilateral hemicord at epicenter, and + 500 µm and + 1000 µm caudal to the epicenter (f). Two weeks-post-
injury, epicenter and perilesional areas (+ 500 µm and + 1000 µm away) of xCT−/− mice contained significantly 
more “type A” Iba1-positive cells. A set of molecular markers was applied to assess microglia polarization 
towards pro-inflammatory or anti-inflammatory profile at 2 weeks post-injury. The gene expression of nox2 
and tnf-a was lower while ym1 and igf-1 were significantly higher in xCT−/− mice (g). Data are expressed as 
mean +/− SEM. *p < 0.05, Mann–Whitney test, n = 3–4 mice/group; ap < 0.05, a’p = 0.059, Mann–Whitney test for 
“type A” microglia between xCT+/+ and xCT−/− mice, n = 4 mice/group; bp < 0.05, Mann–Whitney test for “type 
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of microglia or macrophages is alleviated on the full xCT knock-out background. It is classically described 
that equal amount of M1/pro-inflammatory and M2/anti-inflammatory macrophages/microglia invade the SCI 
lesion within the first  week46–49. At the end of second week post-SCI, M1 macrophages usually outnumbered M2 
 cells46. According to our gene expression profile, the cellular response within the injured spinal tissue was early 
shifted towards an anti-inflammatory phenotype in xCT-deficient mice. In particular, nox2 and tnf-a mRNA 
were significantly lowered while ym1 and igf-1 mRNA levels were upregulated. These findings on pro-to-anti-
inflamatory gene response have been described in a similar context when xCT−/− mice were crossed with mutant 
 SOD1G37R ALS mice and ALS disease course was slowed  down27. Also, xCT-deficiency alleviates the release 
of pro-inflammatory cytokines in the cerebral cortex or hippocampus in a model of LPS-induced post-septic 
neurological psychiatric  illness23,35.
Finally, we sought to decipher whether xCT-deficiency would have an impact on the polarization of the astro-
cyte response during the sub-acute phase of SCI. Although the number of GFAP + astrocytes did not differ, xCT-
deficiency might modulate astrocyte reactivity following nervous trauma. All astrocyte-derived inflammatory 
markers were similarly modulated in both groups. However, lipocalin-2, that is mostly expressed by astrocytes 
under inflammatory  conditions50,51, was induced in injured xCT−/− spinal cords. In models of LPS-induced 
sepsis or retinal degeneration, recent reports have shown that lipocalin-2 can serve as a potent neuroprotective 
factor in response to neuro-inflammation52–54. Surprisingly, knocking-out lipocalin-2 in mice undergoing SCI 
improves functional and histopathological outcomes compared to wild-type  mice55. The contribution of lipoca-
lin-2 in diseases characterized with prominent neuro-inflammation or astrocyte activation is thus still confusing.
The pathological events following SCI involve many cellular and molecular actors that operate in a time-
regulated fashion, so that the only way to aim at deciphering whether System xc− from astrocyte and/or microglia 
modulate neuro-inflammation pathways would be to investigate inducible conditional knock-out mice models. 
So far, our results show that full genetic xCT invalidation modifies functional and histopathological SCI out-
comes. In the future, pharmacological inhibition of System xc-, using BBB-permeant specific inhibitors, might 
be a therapeutic approach in order to accelerate post-SCI recovery in patients.
Methods
Animals. All aspects (ethical, data collection, data analysis) included in this study are reported in accord-
ance with ARRIVE guidelines. The experimental protocol was conducted in compliance with the European 
Communities Council Directives for Animal Experiments (2010/63/EU, 86/609/EEC and 87/848/EEC) and 
was approved by the Animal Ethics Committee of the University of Namur (ethic project UN 17-295). Male 
C57BL/6J mice, aged from 3 to 4 months were included in the study. xCT−/− mice and their xCT+/+ litter-
mates have a C57BL/6J background and are high-generation descendants of the strain described  previously56. 
Genotypes were confirmed by PCR amplification of ear DNA using REDExtract-N-Amp Tissue PCR Kit 
(Sigma-Aldrich, Overijse, BE) and the following primers: 5′-GAT GCC CTT CAG CTC GAT GCG GTT CAC CAG 
-3′ (GFPR3); 5′-CAG AGC AGC CCT AAG GCA CTT TCC -3′ [mxCT5′flankF6]; 5′-CCG ATG ACG CTG CCG ATG 
ATG ATG G-3′ [mxCT(Dr4)R8].
Spinal cord injury. After genotyping, xCT−/− mice and xCT+/+ littermates were randomly subjected to a 
spinal cord contusion. Mice were anesthetized with a cocktail of ketamine (100 mg/kg) and xylazine (5 mg/kg). 
The full SCI procedure was similar as described previously, except that the spinal impact targeted C5-only57. 
Briefly, after incision of the dorsal skin and underlying muscles between C2 and T1 bony processes, the para-
vertebral muscles overlying C4–C6 were removed. A unilateral laminectomy on the right side of C5, extending 
on top of the posterior spinal artery, was performed followed by the stabilization of the spinous processes of 
C2 and T2 using toothed Adson  forceps57. xCT+/+ and xCT−/− mice were subjected to spinal contusion using 
the computer-controlled Infinite Horizon IH400 impactor (Precision Systems and Instrumentation, Lexington, 
USA). The C5 impact was generated with a force set at 50 kD. The impact force sensed by the IH device was 
52.3 ± 0.3 kD (mean ± SEM) for all injuries. The parameters (i.e., displacement and velocity of the tip) are listed 
per genotype in Table 1. None of the parameters were significantly different between xCT+/+ and xCT−/− mice. 
At the end of the surgery, overlying muscles were closed in layers with sterile 4–0 silk suture, and the skin inci-
sion was closed using sterile wound clips. Animals were allowed to recover on a circulating warm water heating 
pad until awake and then returned to their home cages. Animals were monitored on a daily basis for 5 days, and 
measures were taken to avoid dehydration and to minimize any potential pain (subcutaneous administration of 
buprenorphine: 0.1 mg/kg).
Cylinder paw preference test. All behavioral measurements were conducted on mice starting 2 weeks 
before injury and thereafter on a weekly basis until they were sacrificed. Mice were weekly video-recorded while 
rearing freely in a transparent cylinder for 5  min58. This test uses spontaneous rearing and exploratory behavior 
Table 1.  Parameters recorded after computer-controlled SCI contusion. Data are expressed as mean ± SEM.
xCT+/+ xCT −/− Significance
Force (kD) 51.9 ± 0.4 52.7 ± 0.5 p > 0.05
Velocity (mm/sec) 123.0 ± 0.6 122.8 ± 0.4 p > 0.05
Displacement (µm) 669.8 ± 21.3 713.2 ± 19.9 p > 0.05
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to evaluate forelimb asymmetries under a preference paradigm. Three behaviors were scored during vertical 
exploration: use of the right ipsilateral forelimb alone, use of the left contralateral forelimb alone, and use of both 
forelimbs simultaneously. The hit score was expressed as a percentage of usage of each forelimb to total limb 
usage. The video analysis was performed by one investigator (L.S.) who was blinded to the genotypes.
Grip strength test. Muscle grip strength was determined weekly for the ipsilateral (right) forelimb using 
a “grip strength meter” Model GS3 (Bioseb, Vitrolles, France). Grip strength testing was performed by allowing 
the mouse to grasp a thin bar attached to the force  gauge58. This was followed by pulling the animal away from 
the gauge until the forelimb released the bar. The force measurements were averaged from three trials. The test 
was performed by one investigator (C.N.) who was blinded to the genotypes.
In situ hybridization, histology and immunohistochemistry. Tissue processing. Under anesthesia 
(ketamine (100  mg/kg) and xylazine (5  mg/kg)), mice were exsanguinated and transcardially perfused with 
NaCl 0.9% followed by phosphate-buffered 4% paraformaldehyde. Spinal cords were harvested and post-fixed 
overnight in fixative. Cervical spinal regions were then dehydrated, paraffin-embedded and cut into 10-µm serial 
sections.
in situ hybridization (ish). Chromogenic ish detection was performed according to the manufacturer’s pro-
tocol (RNAScope 2.5 HD Detection Reagent RED, #322360, Advanced Cell Diagnostics Inc, Hayward, USA). 
Paraffin-embedded spinal cord sections were incubated at 60 °C for 1 h followed by deparaffinization and dehy-
dration. Endogenous peroxidases were blocked with hydrogen peroxide for 10 min at room temperature (RT) 
followed by 2 washes in milliQ water. Heat-induced epitope retrieval was performed for 15 min at 100 °C using 
RNAScope Target retrieval followed by 2 milliQ washes and a 99% ethanol rinse. Slides were dried at RT and 
hydrophobic barriers were applied. Samples were then incubated with RNAScope protease plus at 40 °C for 
30 min and subsequently washed in milliQ water. Samples were incubated with the probe specifically targeting 
slc7a11 mRNA (RNAScope ref. 422511, Advanced Cell Diagnostics Inc, Hayward, USA) for 2 h at 40 °C and 
then washed for 2 min at RT in RNAScope wash buffer. Amplification rounds 1–6 alternated from 30 to 15 min 
at 40 °C. After each amplification round, samples were washed with RNAScope wash buffer. Signal detection 
was performed by incubating samples with alkaline phosphatase (solution of RNAScope Fast B and A ratio 1:60) 
for 10 min at RT. Samples were then washed in milliQ water. Following ish, samples were either counterstained 
with hematoxylin (Sigma, St Louis, MO), dried for 30 min at 60 °C and mounted using VectaMount (Vector 
Laboratories, Burlingame, USA) or fluorescently stained following the protocol below.
For fluorescent ish/immunofluorescence multiplexing, detection was performed according to the manufac-
turer’s protocol (RNAScope Multiplex Fluorescent Detection Reagent V2, #323110, Advanced Cell Diagnostics 
Inc, Hayward, USA). Briefly, after slc7a11 probe incubation of 2 h at 40 °C (RNAScope ref. 422511-C2, Advanced 
Cell Diagnostics Inc, Hayward, USA), sections were washed with RNAScope wash buffer. Three amplification 
steps were performed and 15 min of HRP C2 incubation at 40 °C was necessary. After 3 × 5 min washes, tissue 
sections were incubated with TSA Plus fluorophore 1:1500 for 30 min at 40 °C. After 15 min incubation of HRP 
blocker at 40 °C, sections were washed in Tris-buffered saline supplemented with 0,1% Tween (TBS-T). Endog-
enous peroxidases were blocked with a mix of horse and goat serum (Dako, Glostrup, Denmark) for 30 min at 
RT. After 3 × 5 min washes, samples were incubated with primary antibodies overnight at RT (Table 2). After 
that, samples were washed with TBS-T. Fluorophore-coupled secondary antibodies alexa fluor 488 anti-mouse 
or anti-rabbit 1:100 (Jackson ImmunoResearch Inc, West Grove, PA) were applied on their respective tissue 
sections and incubated for 30 min at RT. Afterwards, they were washed with TBS-T. Finally, tissue sections were 
coverslipped with ProLong Gold mounting medium containing DAPI (ThermoFisher Scientific, USA).
Lesion histology and motor neuron counting. Using every fifth slide, paraffin sections were dewaxed, rehy-
drated and stained with Eriochrome Cyanine R/Neutral red. Sections were dehydrated, mounted in DPX (Merck 
Millipore, Darmstadt, DE) and imaged using Olympus BX63 upright microscope. Using ImageJ software, the 
lesion area was outlined and quantified from caudal to rostral side around the epicenter. Specifically, the lesion 
area was determined every 150 μm on Neutral Red sections and expressed as a percentage of total area of the 
hemi-spinal cord ipsilateral to the lesion. Injury included areas of both lost tissue and surrounding damaged 
tissue where the normal microanatomical structure of the spinal cord was disrupted. The lesion epicenter was 
considered as the section with the largest percent of injured tissue. As previously described, the lesion volume 
was determined using the Cavalieri estimator of volume equation: V = [Σ (A1 + A2 + ··· + An) × D] − [Amax × 
Y] with A = damaged surface (μm2), D = distance between 2 Sects. (150 μm) and Y = section thickness (10 μm)57.
Table 2.  List of antibodies.
Antigen Supplier - reference Multiplex IF dilution IHC dilution
GFAP Sigma-Aldrich clone GA5–G3893 1 :40 1 :1000
Iba1 Wako Chemicals 019-19741 1 :100 1 :300
MAP2 Genetex 1D7-B9-C8-F6 1 :100 n.a
p25α Sigma-Aldrich HPA-036576 1 :100 1 :300
Vimentin Abcam Ab92547 1 :500 n.a
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In Neutral Red stained sections, the total number of cervical motor neurons was quantified in a blind manner. 
Ventral horn was defined as gray matter ventral to the central canal. Only motor neurons with a clearly identifi-
able nucleus and a cell soma > 150 μm2 were counted.
Immunohistochemistry and glial cell counting. Oligodendrocytes, astrocytes and microglia were revealed 
respectively using anti-p25α, anti-GFAP and anti-Iba1 immunolabelings. Using every fifth slide, paraffin sec-
tions were dewaxed, rehydrated and subjected to heat-induced epitope retrieval in citrate buffer pH 6 at 100 °C 
for 10 min. Endogenous peroxidase activity was abrogated with 3%  H2O2 in methanol for 10 min. To avoid non-
specific binding, a bath of glycine 0,1 M was performed for 3 min followed by a blocking step in 5% goat or horse 
serum diluted in TBS for 30 min. Sections were then incubated overnight at 4 °C with primary antibodies diluted 
in TBS with 1% normal serum (Table 2). The next day, secondary biotinylated antibodies (1:300; Vectastain, ABC 
Kit, USA) were incubated on tissue slices 1 h at room temperature. Sections were then incubated with a solution 
of peroxidase-bound streptavidin (1:200-Vectastain) for 45 min. Immunoreactivity was revealed using 3,3 di-
amino-benzidine (Dako, Glostrup, DK). Finally, sections were counterstained with hemalum, dehydrated and 
mounted in DPX. Each slice was imaged with an Olympus BX63 microscope using the Cell Sens software, and 
the number of immunolabelled cells was counted in the ipsilateral hemicord then plotted rostrally and caudally 
around the lesion epicenter.
Image quantification. Except for neuron counting, the quantification of cell densities was performed in 
the lesion epicenter (0 µm) and two regions caudal to it (respectively at +500 and +1000 µm distances). The epi-
center was set as abovementioned. One slice per region was acquired for each animal and imported into ImageJ 
software (https:// imagej. nih. gov/ ij/). The quantitative evaluation of immunostainings was blindly performed by 
one investigator (L.S.): total immunoreactive cells (GFAP+ , p25a+ or Iba1+) were manually counted within the 
whole ipsilateral hemicord. The morphology of Iba1+ microglial cells was analyzed according to a previously 
described  protocol31. In each hemicord slice, all Iba1+ cells were counted and classified into four types based 
on their morphology. Type A resting: cells have long and very thin processes; Type B ramified: processes are 
long and dense, cytoplasm around nucleus is visible; Type C ramified: processes are shorter and there are many 
branches; Type D amoeboid: there is no more processes, the cell is limited to nucleus and strong immunoreac-
tive cytoplasm.
Western blot and OxyBlot. Proteins were extracted from 2-mm pieces of spinal cord centered on C5 
level. Tissue was crushed using a Tissue Grinder in 200 µl of RIPA lysis buffer for 2 h on ice. After centrifuga-
tion at 13,000×g for 5 min at 4 °C, the quantity of proteins in supernatant was measured with the Pierce protein 
assay kit (Thermo Scientific, Bleiswijk, NL). Samples were mixed with 100 nM DTT and 5% β-mercaptoethanol, 
and incubated 1 h at 37  °C prior to gel loading. Proteins (20 µg) were loaded on a 12% polyacrylamide gel, 
separated via SDS-PAGE and transferred to a PVDF membrane (120 V for 1h30). Membranes were incubated 
with a blocking solution containing 5% milk in TBS-Tween for 30 min, followed by incubation with primary 
antibodies diluted in 5% milk in TBS-Tween at 4 °C overnight. Primary antibodies used were rabbit anti-xCT 
antibody (Cell Signaling Technology #98051S, 1:500), mouse anti-GAPDH (Sigma-Aldrich G8795, 1:10,000) or 
mouse anti-β-actin antibody (Sigma-Aldrich A5441, 1:10,000) diluted in 5% TBS-BSA. Specificity of xCT anti-
body was carefully investigated using negative and positive tissue controls (Supplementary Fig. 1). Detection of 
protein carbonyls formation was performed using an OxyBlot kit according to the manufacturer’s instructions 
(cat #S7150; Merck Millipore). Membranes were then rinsed and incubated with an anti-rabbit or an anti-mouse 
HRP-linked antibody (Cell Signaling #7074S or #7076S) diluted 1:1000 in 5% milk in TBS-Tween. Signal was 
revealed using a chemiluminescent method (BM chemiluminescence blotting substrate (POD), Roche Diag-
nostics, Mannheim, DE) and imaged on an Image Quant LAS 4000 mini using LAS 4000 luminescent image 
analyzer (GE Healthcare, Diegem, BE). The number of pixels for each band-of-interest was quantified after 
importation in ImageJ and expressed as related to the respective loading control (GAPDH).
Glutathione assay. Two-mm pieces of spinal cord centered on C5 level were homogenized in ice-cold PBS. 
Homogenates were centrifuged for 15 min at 10,000×g and the protein content of the supernatant was deter-
mined using the Pierce protein assay kit (Thermo Scientific, Bleiswijk, NL). The GSH content of the supernatant 
was analyzed using a QuantiChrom GSH Assay Kit according to the instructions of the manufacturer (BioAssay 
Systems, Hayward, USA).
RNA isolation and qRT-PCR. Two-mm pieces of spinal cord centered on C5 level were homogenized in 
Trizol reagent (Life Technologies, Bleiswijk, NL). Total RNA was further isolated according to the manufac-
turer’s instructions including a step of purification using the High Pure RNA Tissue Kit (Roche Diagnostics, 
Basel, CH). RNA concentrations were measured using a spectrophotometer Nanodrop 1000 (Thermo Scientific, 
Bleiswijk, NL). One µg of total RNA was reverse-transcribed using the High Capacity cDNA Reverse Transcrip-
tion Kit according to the manufacturer’s instructions, including DNAse treatment (Applied Biosystems, Thermo 
Fisher Scientific Baltics, LT). One µL of cDNA was amplified using specific primers targeting genes-of-interest 
with the Takyon SYBR Green according to the manufacturer’s instructions (Eurogentec, Liège, BE) in the Light 
Cycler 96 system (Roche Diagnostics, Mannheim, DE). Primer sequences are listed in Table 3. Specific amplifica-
tion was confirmed by melting curve analysis. Relative gene expression was computed using the 2-ddCq method 
with HPRT as housekeeping gene.
Statistical analysis. Unless specified, all results were expressed as mean values ± Standard Error of Mean 
(SEM). The data were statistically analyzed using an unpaired T-test when data were spread according to a 
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Gaussian distribution or using a non-parametric Mann–Whitney test in the other cases. For multiple compari-
sons, one-way (Kruskal–Wallis) or two-way ANOVA tests were also used depending on the number of variables 
analyzed. The level of significance was set at p < 0.05. The statistical analyses were performed by using the soft-
ware GraphPad Prism version 7 (GraphPad Software, La Jolla, USA).
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